coremap

Executive Summary

CoreMap is a privately held medical device company headquartered in Cambridge, Massachusetts, dedicated to developing an advanced diagnostic platform for visualizing and treating atrial fibrillation (AF). The company’s technology aims to provide electrophysiologists with ultra-high-resolution, patient-specific mapping of complex atrial arrhythmias, thereby enabling more precise ablation procedures. Founded in 2018 by a clinical electrophysiologist and an experienced medtech executive, CoreMap addresses a critical unmet need in the management of persistent AF, where traditional mapping techniques often fall short. By improving procedural accuracy and outcomes, CoreMap’s solution has the potential to reduce recurrence rates, lower healthcare costs, and enhance quality of life for millions of AF patients worldwide. CoreMap operates in the competitive cardiovascular medical device space, with a focus on the growing AF ablation market. The company is still in the development stage and has not disclosed its total funding or clinical milestones to date. Given the nascent stage of its technology, CoreMap faces risks typical of early-stage medtech ventures, including regulatory hurdles, clinical validation requirements, and the need for substantial capital. However, the strong clinical foundation of its founders and the clear demand for better AF mapping tools position CoreMap as a compelling opportunity for investors and strategic partners seeking exposure to innovation in cardiac electrophysiology.

Upcoming Catalysts (preview)

• TBDCompletion of First-in-Human Clinical Study40% success
• TBDFDA 510(k) Submission or Clearance30% success
• TBDSeries A or B Financing Round50% success